Modeling prostate cancer in mice: limitations and opportunities.
Modeling prostate cancer in mice: limitations and opportunities.
复制标题
DOI：
10.2164/jandrol.111.013987
复制
发表时间：
2012-03
影响因子：
--
通讯作者：
Kyprianou N
中科院分区：
文献类型：
--
作者：
Hensley PJ;Kyprianou N
肿瘤微环境和前列腺癌异质性的复杂动态影响了建立合适的临床前小鼠模型来代表人类癌症从早期增殖表型到侵袭性、雄激素非依赖性和侵袭性转移性肿瘤进展的努力。目前的模型已经成功地克服了侵袭性肿瘤的个体特征。然而，这些模型都没有全面模拟人类癌症的进展，这给利用它们研究人类疾病带来了挑战。通过针对特定分子途径复合突变来定制小鼠表型结果的能力，为破坏导致去势抵抗性前列腺癌发生和进展的信号途径提供了强大的工具。每个模型都具有有助于理解前列腺肿瘤发生的独特特征，以及挑战我们对癌症发生和进展机制的了解的局限性。新兴策略利用基因组操作技术来规避这些限制，以制定有吸引力的、生理相关的前列腺癌进展到晚期疾病的模型。本综述讨论了广泛使用且特征明确的前列腺癌进展至转移小鼠模型的当前价值，以及开发新模型以测试治疗策略的抗肿瘤功效和识别疾病进展的新生物标志物的机会。
The complex dynamics of the tumor microenvironment and prostate cancer heterogeneity have confounded efforts to establish suitable preclinical mouse models to represent human cancer progression from early proliferative phenotypes to aggressive, androgen-independent, and invasive metastatic tumors. Current models have been successful in capitulating individual characteristics of the aggressive tumors. However, none of these models comprehensively mimics human cancer progression, establishing the challenge in their exploitation to study human disease. The ability to tailor phenotypic outcomes in mice by compounding mutations to target specific molecular pathways provides a powerful tool toward disruption of signaling pathways contributing to the initiation and progression of castration-resistant prostate cancer. Each model is characterized by unique features contributing to the understanding of prostate tumorigenesis, as well as limitations challenging our knowledge of the mechanisms of cancer development and progression. Emerging strategies utilize genomic manipulation technology to circumvent these limitations toward the formulation of attractive, physiologically relevant models of prostate cancer progression to advanced disease. This review discusses the current value of the widely used and well-characterized mouse models of prostate cancer progression to metastasis, as well as the opportunities begging exploitation for the development of new models for testing the antitumor efficacy of therapeutic strategies and identifying new biomarkers of disease progression.
登录
查看更多内容
影响因子：
11.2
作者：
Asatiani, E;Huang, WX;Gelmann, EP
通讯作者：
Gelmann, EP
影响因子：
56.9
作者：
Di Cristofano, A;Kotsi, P;Pandolfi, PP
通讯作者：
Pandolfi, PP
影响因子：
4.8
作者：
Bieberich, CJ;Fujita, K;Jay, G
通讯作者：
Jay, G
影响因子：
4.8
作者：
Gingrich, JR;Barrios, RJ;Greenberg, NM
通讯作者：
Greenberg, NM
DOI：
10.1073/pnas.0407693101
发表时间：
2004-12-07
影响因子：
11.1
作者：
Gao, H;Ouyang, X;Abate-Shen, C
通讯作者：
Abate-Shen, C